New ADC Shrinks HER2-Positive Tumors
- PMID: 31375517
- DOI: 10.1158/2159-8290.CD-NB2019-089
New ADC Shrinks HER2-Positive Tumors
Abstract
A phase I trial reported positive results for an antibody-drug conjugate that targets HER2-positive tumors. Trastuzumab duocarmazine, which kills tumor cells by causing DNA damage, induced partial responses in 33% of patients whose tumors were resistant to the approved antibody-drug conjugate trastuzumab emtansine. The drug caused fatigue, neutropenia, pneumonitis, and eye-related side effects.
©2019 American Association for Cancer Research.
Comment on
-
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.Lancet Oncol. 2019 Aug;20(8):1124-1135. doi: 10.1016/S1470-2045(19)30328-6. Epub 2019 Jun 27. Lancet Oncol. 2019. PMID: 31257177 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
